Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
HIV Eradication: One Step Closer
Scientists Crack Integrase Inhibitor Mystery
Gilead Reports Success With Quad Pill and Boosting Drug
New Hope for HIV Eradication
Study: Demand for HIV Vaccine Will Depend on How Good It Is
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

December 21, 2007

Isentress Wins Approval in European Union

The HIV integrase inhibitor Isentress (raltegravir) was approved in the European Union today for use in combination with other antiretrovirals for treatment-experienced patients who have detectable viral loads despite ongoing antiretroviral therapy.

The approval of Isentress, developed and manufactured by Merck & Co., allows for access to the drug in the 27 European Union countries, as well as Norway and Iceland. It was approved earlier this year in the United States, Canada and Mexico.

Isentress is a promising HIV drug for treatment-experienced patients with drug-resistant virus because it works differently than other available antiretrovirals. After HIV’s genetic material is deposited inside a cell, its RNA must be converted (reverse transcribed) into DNA. A viral enzyme called integrase then helps to hide HIV’s DNA inside the cell’s DNA. Once this happens, the cell can begin producing genetic material for new viruses. Integrase inhibitors, such as Isentress, are designed to block the activity of the integrase enzyme and to prevent HIV DNA from meshing with healthy cell DNA.


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 4 (of 4 total)    

Chris, San Francisco, 2007-12-29 23:02:56
Hey Ken from Lauderhil, or anyone else taking Isentress, what's your experience with side effects on this med? Any lipo side effects or others you've experience so far?

peter abbott, san francisco, 2007-12-28 02:26:16
News about approval in the EU is interesting for me because I have coverage in Austria and have found in the past that Austria does its own approval process and sadly if they choose to "save" money, they don't even consider the approval process. So thus it is not approved. Expensive meds are thus kept out of the country or on self-pay.

Ken, Lauderhill FL, 2007-12-27 17:39:20
I started on Isentress the beginning of Oct 07 and in 30days of being on the med my viral load when undecided for the first time in 16yrs

Richard Dow, Nyack, NY 10960, 2007-12-26 13:42:31
Is Isentress approved for use in USA? In process? Or how soon might it be approved? Thanks R.

comments 1 - 4 (of 4 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16-19, 2010


5th IAS Conference on HIV Pathogenesis Treatment and Prevention (IAS 2009)
Cape Town, South Africa
July 19-22, 2009


16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Montréal, Canada
February 8-11, 2009

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy